Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Sudeep Pharma IPO
Price Band
₹563.0–593.0
Issue Size
₹895.0 Cr
Lot Size
25 shares
Min Investment
₹14,825
GMP
+₹121.0 (20.4%)
Issue Price
₹593.0
Subject to Sauda
₹2300
Paid only if allotted
Sudeep Pharma IPO AI Summary
- Sudeep Pharma IPO is listed on BSE, NSE in the Specialty Chemicals sector.
- Price band: ₹563.0–₹593.0 per share, lot size 25 shares (min. investment ₹14,825).
- Subscription window: 21 Nov–25 Nov 2025, listing on 28 Nov 2025.
- Current GMP is +₹121.0 (20.4%), an estimated listing price of ₹714 — unofficial and can change daily.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Sudeep Pharma IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 25 Nov 2025 — not a current signal.
2 of 2 reviewers say Neutral
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Sudeep Pharma IPO Grey Market Premium (GMP) Today
GMP
+₹121.0
GMP %
+20.4%
Est. Listing
₹714.0
Updated: 25 Jul 2026 14:15
About the Company
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries. The company operates six manufacturing facilities with a combined production capacity of 50,000 MT, specializing in minerals such as calcium, iron, magnesium, zinc, potassium, and sodium The company supplies more than 200 products to a diverse customer base across pharma, food, and nutrition sectors The company has strong R&D capabilities with in-house labs and pilot-scale facilities focused on mineral salts and excipients. Product Portfolio: Pharmaceutical, Food and Nutrition Business Specialty Ingredients Business Triturates As of December 31, 2024, the company had 704 permanent employees. Competitve Strengths: Market leadership with a diversified product portfolio in a high barrier industry Distinguished global customer base with long-standing relationships with key customers Well-equipped and regulatory compliant Manufacturing Facilities Strong research and development capabilities
Company Financials (₹ Cr)
As of 2025-06-30
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 922.26 | 717.17 | 513.87 | 420.11 |
| Total Income | 130.08 | 511.33 | 465.38 | 438.26 |
| Profit After Tax | 31.27 | 138.69 | 133.15 | 62.32 |
| EBITDA | 48.57 | 199.28 | 187.76 | 98.64 |
| NET Worth | 688.32 | 497.53 | 359.07 | 226.29 |
| Reserves and Surplus | 668.52 | 481.11 | 354.59 | 221.88 |
| Total Borrowing | 135.97 | 135.25 | 75.03 | 82.26 |
Key Ratios
EPS
₹12.46
NAV
₹45.86
RoNW
27.88%
P/B Value
12.93
P/E Ratio
47.61
Market Cap
₹6697.85 Cr
PAT Margin
27.63%
Debt/Equity
0.20
Promoters
Sujit Jaysukh Bhayani, Avani Sujit Bhayani, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani (HUF), Riva Resources Pvt.Ltd. and Bhayani Family Trust
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I 75.81 2 General Corporate Purposes 12.67 3 Issue Expenses 61.97 Total 150.45
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total Income was ₹438.26 Cr in the year ending 31 Mar 2023, increasing to ₹465.38 Cr by 31 Mar 2024, and further rising to ₹511.33 Cr by 31 Mar 2025. However, for the period ending 30 Jun 2025, Total Income was ₹130.08 Cr, which is not directly comparable as it represents a 9-month figure.
Profit Trend
Profit After Tax was ₹62.32 Cr in the year ending 31 Mar 2023, increasing to ₹133.15 Cr by 31 Mar 2024, and further rising to ₹138.69 Cr by 31 Mar 2025. For the period ending 30 Jun 2025, Profit After Tax was ₹31.27 Cr, which is a 9-month figure and not directly comparable.
Grey Market Premium, Explained
The Grey Market Premium (GMP) indicates the expected listing price of an IPO based on unofficial trading before its official listing. A positive GMP suggests that the market anticipates the stock to list at a higher price than the issue price.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their investment goals and market conditions. It's important to consider the company's fundamentals and growth potential.
Who May Want to Wait
Investors with a low-risk appetite or those who prefer stable returns may want to approach IPOs like this with caution, as they can be subject to market fluctuations and uncertainties.
IPO Timeline, Explained
The IPO opens for subscription on November 21, 2025, and closes on November 25, 2025. Allotment of shares will be done by November 26, 2025, and the listing is expected on November 28, 2025.
Listing Gains — The Risk
Listing gains refer to the potential profit an investor can make when the stock lists at a higher price than the issue price. However, these gains are not guaranteed, and the stock's performance can fluctuate based on market conditions and investor sentiment.
This evaluation is generated from Sudeep Pharma's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Sudeep Pharma IPO GMP today?
Sudeep Pharma IPO GMP today is +₹121.0 (20.4%), indicating an estimated listing price of ₹714. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Sudeep Pharma IPO?
The price band of Sudeep Pharma IPO is ₹563.0–₹593.0 per share.
When does Sudeep Pharma IPO open and close?
Sudeep Pharma IPO opens on 21 November 2025 and closes on 25 November 2025.
When does Sudeep Pharma IPO list on the stock exchange?
Sudeep Pharma IPO listed on 28 November 2025 at ₹714.0.
What is the lot size for Sudeep Pharma IPO?
The lot size for Sudeep Pharma IPO is 25 shares, requiring a minimum investment of ₹14,825.
What is the price band for the Sudeep Pharma IPO?
The price band for the Sudeep Pharma IPO is ₹563.0 to ₹593.0.
What is the minimum investment required?
The minimum investment required is ₹14,825.0.
What is the lot size for the IPO?
The lot size for the Sudeep Pharma IPO is 25 shares.
When is the listing date for the IPO?
The listing date for the Sudeep Pharma IPO is November 28, 2025.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected listing price of an IPO based on unofficial trading before its official listing.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
21 Nov 2025
Close
25 Nov 2025
Allotment
26 Nov 2025
Listing
28 Nov 2025
Similar IPOs in Specialty Chemicals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Sudeep Pharma?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.